Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Abstract

The management of hemophilia A has undergone a remarkable revolution, in line with technological advancement. In the recent past, the primary concern associated with Factor VIII (FVIII) concentrates was the risk of infections, which is now almost resolved by advanced blood screening and viral inactivation methods. Improving patients' compliance with prophylaxis has become a key focus, as it can lead to improved health outcomes and reduced health care costs in the long term. Recent bioengineering research is directed toward prolonging the recombinant FVIII (rFVIII) coagulant activity and synthesising higher FVIII yields. As an outcome, B-domain deleted, polyethylene glycolated, single-chain, Fc-fused rFVIII, and rFVIIIFc-von Willebrand Factor-XTEN are available for patients. Moreover, emicizumab, a bispecific antibody, is commercially available, whereas fitusiran and tissue factor pathway inhibitor are in clinical trial stages as alternative strategies for patients with inhibitors. With these advancements, noninfectious complications, such as inhibitor development, allergic reactions, and thrombosis, are emerging concerns requiring careful management. In addition, the recent approval of gene therapy is a major milestone toward a permanent cure for hemophilia A. The vast array of treatment options at our disposal today empowers patients and providers alike, to tailor therapeutic regimens to the unique needs of each individual. Despite significant progress in modern treatment options, these highly effective therapies are markedly more expensive than conventional replacement therapy, limiting their access for patients in developing countries.

Keywords

hemophilia A - factor VIII - gene therapy - bioengineering - emicizumab - half-life - safety

Publication History

Article published online:
15 January 2024

• References

• 1 Wynn TT, Gumuscu B. Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med 2016; 7: 121-128
• 2 World Federation of Hemophilia. World Federation of Hemophilia report on the annual global survey 2022. WFH:Montréal Canada 2023. Available from: https://www1.wfh.org/publications/files/pdf-2399.pdf
• 3 Roth DA, Tawa Jr NE, O'Brien JM, Treco DA, Selden RF. Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344 (23) 1735-1742
• 4 Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
• 5 Graw J, Brackmann H-H, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005; 6 (06) 488-501
• 6 Gouw SC, van der Bom JG, Ljung R. et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (03) 231-239
• 7 Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105 (03) 545-553
• 8 Catelli D, Portich JP, Calvache ET. et al Hemophilia: a biography on therapeutical approaches. Clin Biomed Res 2023;43(01):
• 9 Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016; 388 (10040): 187-197
• 10 Rangarajan S, Walsh L, Lester W. et al. AAV5–factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377 (26) 2519-2530
• 11 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
• 12 Keam SJ. Efanesoctocog alfa: first approval. Drugs 2023; 83 (07) 633-638
• 13 Philippidis A. BioMarin's ROCTAVIAN wins food and drug administration approval as first gene therapy for severe hemophilia A. Hum Gene Ther 2023; 34 (15-16): 665-668
• 14 Arcieri R, Calizzani G, Candura F, Mannucci PM. The increased demand for plasma-derived factor VIII in Italy. Blood Transfus 2017; 15 (03) 279-280
• 15 Kevane B, O'Connell N. The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A. Transfus Apheresis Sci 2018; 57 (04) 502-506
• 16 Kohar K, Prayogo SA, Wiyono L. The impact of recombinant versus plasma-derived factor VIII concentrates on inhibitor development in previously untreated patients with hemophilia A: a 2021 update of a systematic review and meta-analysis. Cureus 2022; 14 (06) e26015
• 17 Neufeld EJ, Sidonio Jr RF, O'Day K, Runken MC, Meyer K, Spears J. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. J Med Econ 2018; 21 (08) 762-769
• 18 Peyvandi F, Mannucci PM, Garagiola I. et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
• 19 Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR. sippet study group. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost 2018; 16 (01) 39-43
• 20 Blatný J, Kardos M, Miljic P. et al. Incidence of inhibitor development in PUPs with severe haemophilia A in the CEE region between 2005 and 2015. Thromb Res 2021; 198: 196-203
• 21 Nathwani AC, Davidoff AM, Tuddenham EGD. Advances in gene therapy for hemophilia. Hum Gene Ther 2017; 28 (11) 1004-1012
• 22 Klamroth R, Gröner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion 2014; 54 (05) 1406-1417
• 23 Farrugia A, Liumbruno GM, Candura F, Profili S, Cassar J. Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia. Blood Transfus 2018; 16 (06) 525-534
• 24 Chen C, Fang X-D, Zhu J. et al. The gene expression of coagulation factor VIII in mammalian cell lines. Thromb Res 1999; 95 (02) 105-115
• 25 Carr Jr ME. Future directions in hemostasis: normalizing the lives of patients with hemophilia. Thromb Res 2010; 125 (Suppl 1): S78-S81
• 26 Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?. J Blood Med 2017; 8: 67-73
• 27 Azzi A, De Santis R, Morfini M. et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001; 98 (08) 2571-2573
• 28 Azzi A, Maggi F, Zakrzewska K. et al. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification. Transfusion 2006; 46 (07) 1162-1167
• 29 Ling G, Tuddenham EGD. Factor VIII: the protein, cloning its gene, synthetic factor and now - 35 years later - gene therapy; what happened in between?. Br J Haematol 2020; 189 (03) 400-407
• 30 Josephson CD, Abshire T. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?. Clin Adv Hematol Oncol 2004; 2 (07) 441-446
• 31 Morfini M. Innovative approach for improved rFVIII concentrate. Eur J Haematol 2014; 93 (05) 361-368
• 32 Ellgaard TW, Bindslev L, Kamstrup S. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa. Protein Expr Purif 2017; 129: 94-100
• 33 Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia 2010; 16 (05) 717-725
• 34 Santagostino E. A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther 2014; 8: 2507-2515
• 35 Ling G, Nathwani AC, Tuddenham EGD. Recent advances in developing specific therapies for haemophilia. Br J Haematol 2018; 181 (02) 161-172
• 36 Mannully ST, Ramya LN, Pulicherla KK. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII. Int J Biol Macromol 2018; 119: 496-504
• 37 Tiede A, Brand B, Fischer R. et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11 (04) 670-678
• 38 Kannicht C, Ramström M, Kohla G. et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013; 131 (01) 78-88
• 39 Hu Z, Li Z, Wu Y. et al. Targeted B-domain deletion restores F8 function in human endothelial cells and mice. Signal Transduct Target Ther 2022; 7 (01) 189
• 40 Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15 (06) 1187-1196
• 41 Miao HZ, Sirachainan N, Palmer L. et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103 (09) 3412-3419
• 42 Sandberg H, Almstedt A, Brandt J. et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85 (01) 93-100
• 43 Recht M, Nemes L, Matysiak M. et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15 (04) 869-880
• 44 Kessler CM, Gill JC, White II GC. et al. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia 2005; 11 (02) 84-91
• 45 Schiavoni M, Napolitano M, Giuffrida G. et al. Status of recombinant factor VIII concentrate treatment for hemophilia a in Italy: characteristics and clinical benefits. Front Med (Lausanne) 2019; 6: 261
• 46 Mathias MC, Collins PW, Palmer BP. et al; United Kingdom Haemophilia Centre Doctors' Organisation Inhibitor Working Party. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia 2018; 24 (06) 896-901
• 47 Aledort L, Ljung R, Mann K, Pipe S. Factor VIII therapy for hemophilia A: current and future issues. Expert Rev Hematol 2014; 7 (03) 373-385
• 48 Graf L. Extended half-life factor VIII and factor IX preparations. Transfus Med Hemother 2018; 45 (02) 86-91
• 49 Srivastava A, Santagostino E, Dougall A. et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia. Haemophilia 2020; 26 (Suppl 6): 1-158
• 50 Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: the ups and downs of treatment. Blood Rev 2021; 50: 100852
• 51 Coppola A, Franchini M, Pappagallo G. et al. Current choices and management of treatment in persons with severe hemophilia A without inhibitors: a mini-Delphi consensus. J Clin Med 2022; 11 (03) 801
• 52 Schmidbauer S, Witzel R, Robbel L. et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res 2015; 136 (02) 388-395
• 53 Klamroth R, Simpson M, von Depka-Prondzinski M. et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. Haemophilia 2016; 22 (05) 730-738
• 54 Mahlangu J, Kuliczkowski K, Karim FA. et al; AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood 2016; 128 (05) 630-637
• 55 Bonanad S, Núñez R, Poveda JL. et al. Matching-adjusted indirect comparison of efficacy and consumption of rVIII-SingleChain versus two recombinant FVIII products used for prophylactic treatment of adults/adolescents with severe haemophilia A. Adv Ther 2021; 38 (09) 4872-4884
• 56 Mahlangu J, Abdul Karim F, Stasyshyn O. et al. Recombinant single-chain factor VIII in severe hemophilia: long-term safety and efficacy in previously treated patients in the AFFINITY extension study. Res Pract Thromb Haemost 2022; 6 (02) e12665
• 57 Borchiellini A, Castaman G, Feola G. et al. Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians. J Thromb Thrombolysis 2022; 53 (04) 934-944
• 58 Pipe SW. New therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2016; 2016 (01) 650-656
• 59 Turecek PL, Bossard MJ, Graninger M. et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32 (Suppl 1): S29-S38
• 60 Mei B, Pan C, Jiang H. et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116 (02) 270-279
• 61 Agersoe H, Stennicke H, Pelzer H. et al. Prolonged effect of N8-Gp in haemophilia A dogs supports less frequent dosing. J Thromb Haemost 2011; 9 (suppl 2): 115
• 62 Zadeh Mehrizi T, Mousavi Hosseini K. An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010-2020 review. Nanoscale Adv 2021; 3 (13) 3730-3745
• 63 Konkle BA, Stasyshyn O, Chowdary P. et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126 (09) 1078-1085
• 64 Shah A, Coyle T, Lalezari S. et al. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies. Haemophilia 2018; 24 (05) 733-740
• 65 Mullins ES, Stasyshyn O, Alvarez-Román MT. et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia 2017; 23 (02) 238-246
• 66 Giangrande P, Andreeva T, Chowdary P. et al; Pathfinder™2 Investigators. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost 2017; 117 (02) 252-261
• 67 Rode F, Almholt K, Petersen M. et al. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. J Thromb Haemost 2018; 16 (06) 1141-1152
• 68 Balkaransingh P, Young G. Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol 2018; 9 (02) 49-61
• 69 Ar MC, Balkan C, Kavaklı K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol 2019; 36 (03) 141-154
• 70 Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med 2017; 6 (04) 39
• 71 Mahlangu J, Powell JS, Ragni MV. et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (03) 317-325
• 72 Young G, Mahlangu J, Kulkarni R. et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13 (06) 967-977
• 73 Zhou JY, Barnes RFW, Foster G, Iorio A, Cramer TJ, von Drygalski A. Joint bleeding tendencies in adult patients with hemophilia: it's not all pharmacokinetics. Clin Appl Thromb Hemost 2019; 25: 1076029619862052
• 74 Malec L, Van Damme A, Chan AKC. et al. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood 2023; 141 (16) 1982-1989
• 75 Rayes J, Lacroix-Desmazes S. A molecular jewel for hemophilia A treatment. Blood 2020; 135 (17) 1417-1419
• 76 Mannucci PM. Growing weapons to fight hemophilia. Bleeding, Thrombosis, and Vascular Biology 2023;2(01):
• 77 Seth Chhabra E, Liu T, Kulman J. et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood 2020; 135 (17) 1484-1496
• 78 Podust VN, Balan S, Sim B-C. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J Control Release 2016; 240: 52-66
• 79 Konkle BA, Shapiro AD, Quon DV. et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020; 383 (11) 1018-1027
• 80 von Drygalski A, Chowdary P, Kulkarni R. et al; XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388 (04) 310-318
• 81 Chun H, Pettersson JR, Shestopal SA. et al. Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products. J Thromb Haemost 2021; 19 (04) 954-966
• 82 ADVATE- antihemophilic factor (recombinant). Takeda Pharmaceuticals America, Inc. 2023
• 83 Curry N, Albayrak C, Escobar M. et al. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia 2019; 25 (03) 373-381
• 84 Chowdary P. Extended half-life recombinant products in haemophilia clinical practice - expectations, opportunities and challenges. Thromb Res 2020; 196: 609-617
• 85 Collins P, Chalmers E, Chowdary P. et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 2016; 22 (04) 487-498
• 86 Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII-a critical review of the evidence. Haemophilia 2018; 24 (03) 348-358
• 87 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019; 17 (06) 479-486
• 88 Mannucci PM. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin Investig Drugs 2020; 29 (03) 303-309
• 89 Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49-56
• 90 Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021; 397 (10274): 630-640
• 91 Demain S, Gonçalves A-C, Areia C. et al. Living with, managing and minimising treatment burden in long term conditions: a systematic review of qualitative research. PLoS One 2015; 10 (05) e0125457
• 92 Gogia P, Tarantino M, Schramm W, Aledort L. New directions to develop therapies for people with hemophilia. Expert Rev Hematol 2023; 16 (06) 417-433
• 93 Klamroth R, Feistritzer C, Friedrich U. et al. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). J Thromb Haemost 2020; 18 (02) 341-351
• 94 Astermark J. Inhibitor development: patient-determined risk factors. Wiley Online Library; 2010
• 95 Kitazawa T, Igawa T, Sampei Z. et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
• 96 Sampei Z, Igawa T, Soeda T. et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8 (02) e57479
• 97 Uchida N, Sambe T, Yoneyama K. et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641
• 98 Shima M, Hanabusa H, Taki M. et al. Factor VIII–mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374 (21) 2044-2053
• 99 McCary I, Guelcher C, Kuhn J. et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia 2020; 26 (04) 631-636
• 100 Shima M, Nogami K, Nagami S. et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25 (06) 979-987
• 101 Young G, Liesner R, Chang T. et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134 (24) 2127-2138
• 102 Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2021; 137 (03) 410-419
• 103 Callaghan MU, Negrier C, Paz-Priel I. et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood 2021; 137 (16) 2231-2242
• 104 Sehgal A, Barros S, Ivanciu L. et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (05) 492-497
• 105 Pasi KJ, Lissitchkov T, Mamonov V. et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort. J Thromb Haemost 2021; 19 (06) 1436-1446
• 106 Srivastava A, Rangarajan S, Kavakli K. et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol 2023; 10 (05) e322-e332
• 107 Young G, Srivastava A, Kavakli K. et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet 2023; 401 (10386): 1427-1437
• 108 Kenet G, Nolan B, Matsushita T. et al. Fitusiran prophylaxis improves health-related quality of life in people with hemophilia A or B, with or without inhibitors: results of ATLAS-PPX study. Blood 2022; 140 (Suppl 1): 7977-7978
• 109 Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123 (19) 2934-2943
• 110 Shapiro AD, Angchaisuksiri P, Astermark J. et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood 2019; 134 (22) 1973-1982
• 111 Seremetis SV, Cepo K, Rasmussen JS. et al. Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events. Blood 2020; 136: 40
• 112 Matsushita T, Shapiro A, Abraham A. et al; explorer7 Investigators. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med 2023; 389 (09) 783-794
• 113 Trinchero A, Sholzberg M, Matino D. The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges. Hamostaseologie 2020; 40 (03) 311-321
• 114 Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost 2019; 17 (09) 1470-1477
• 115 Ferrante F, Ingham S, Kunze M, Michaels L. Anti-TFPI antibody BAY 1093884: early termination of phase II dose escalation study due to thrombosis. Haemophilia 2020; 26 (S2): 77-78
• 116 Aledort LM. Deaths associated with emicizumab in patients with hemophilia A. N Engl J Med 2019; 381 (19) 1878-1879
• 117 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
• 118 Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv 2020; 4 (09) 2111-2118
• 119 Shinohara S, Saito T, Noguchi-Sasaki M, Ishiwata T, Morris M. Evaluation of emicizumab calibrator and controls with a modified one-stage FVIII assay on an automated coagulation analyzer. Res Pract Thromb Haemost 2019; 3 (suppl 1): Abstract PB13055
• 120 Leksa NC, Aleman MM, Goodman AG, Rabinovich D, Peters R, Salas J. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence. J Thromb Haemost 2019; 17 (07) 1044-1052
• 121 Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica 2019; 104 (08) e380-e382
• 122 Arruda VR, Doshi BS, Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions. F1000 Res 2018; 7: 7
• 123 Samuelson Bannow B, Recht M, Négrier C. et al. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev 2019; 35: 43-50
• 124 Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood 2017; 130 (23) 2463-2468
• 125 Timmins P. Industry update: the latest developments in the field of therapeutic delivery, November 2021. Ther Deliv 2022; 13 (03) 141-156
• 126 Baruteau J, Waddington SN, Alexander IE, Gissen P. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J Inherit Metab Dis 2017; 40 (04) 497-517
• 127 Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: recent advances. Int J Mol Sci 2021; 22 (14) 7647
• 128 Pasi KJ, Rangarajan S, Mitchell N. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 2020; 382 (01) 29-40
• 129 Brown HC, Zakas PM, George SN, Parker ET, Spencer HT, Doering CB. Target-cell-directed bioengineering approaches for gene therapy of hemophilia A. Mol Ther Methods Clin Dev 2018; 9: 57-69
• 130 Zakas PM, Brown HC, Knight K. et al. Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction. Nat Biotechnol 2017; 35 (01) 35-37
• 131 Rajavel K, Ayash-Rashkovsky M, Tang Y. et al. Co-prevalence of pre-existing immunity to different serotypes of adeno-associated virus (AAV) in adults with hemophilia. Blood 2019; 134: 3349
• 132 Nault J-C, Datta S, Imbeaud S. et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015; 47 (10) 1187-1193
• 133 Ozelo MC, Mahlangu J, Pasi KJ. et al; GENEr8-1 Trial Group. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022; 386 (11) 1013-1025
• 134 Pasi KJ, Laffan M, Rangarajan S. et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia 2021; 27 (06) 947-956
• 135 VandenDriessche T, Pipe SW, Pierce GF, Kaczmarek R. First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy. Mol Ther 2022; 30 (11) 3335-3336
• 136 Björkman S, Blanchette VS, Fischer K. et al; Advate Clinical Program Group. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8 (04) 730-736
• 137 Dargaud Y, Delavenne X, Hart DP, Meunier S, Mismetti P. Individualized PK-based prophylaxis in severe haemophilia. Haemophilia 2018; 24 (Suppl 2): 3-17
• 138 Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125 (13) 2038-2044
• 139 Iorio A, Edginton AN, Blanchette V. et al. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res Pract Thromb Haemost 2018; 2 (03) 535-548
• 140 Hazendonk HCAM, van Moort I, Mathôt RAA. et al; OPTI-CLOT study group. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?. Blood Rev 2018; 32 (04) 265-271
• 141 McEneny-King A, Foster G, Iorio A, Edginton AN. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo). JMIR Res Protoc 2016; 5 (04) e232
• 142 Arvanitakis A, Berntorp E, Astermark J. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa. Haemophilia 2021; 27 (03) 417-424
• 143 Goedhart TMHJ, Janssen A, Mathôt RAA, Cnossen MH. OPTI-CLOT Study Group and SYMPHONY Consortium. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators. Blood Rev 2023; 61: 101098
• 144 Batorova A, Boban A, Brinza M. et al. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. J Med Life 2022; 15 (04) 570-578
• 145 Lissitchkov T, Rusen L, Georgiev P. et al. PK-guided personalized prophylaxis with Nuwiq^® (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia 2017; 23 (05) 697-704
• 146 Pasi KJ. Efficacy of Nuwiq^® (Simoctocog Alfa) in patients with hemophilia A who changed and adhered to a pharmacokinetic-guided prophylaxis regimen in the NuPreviq Study. Clin Med Insights Blood Disord 2021; 14: 2634853521991517
• 147 Nagao A, Yeung CHT, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thromb Res 2019; 173: 79-84
• 148 Wang Y, Yang Q, Zheng L. et al. Efficacy of individualized preventive treatment of patients with severe hemophilia A guided by multiple clinical parameters and pharmacokinetics. Acta Haematol 2022; 145 (04) 354-361
• 149 Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Subcommittee on Factor VIII, Factor IX, and Rare Bleeding Disorders. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (07) 1437-1441
• 150 Croteau SE, Callaghan MU, Davis J. et al. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost 2018; 2 (03) 607-614
• 151 Valke LLFG, Bukkems LH, Barteling W. et al. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. J Thromb Haemost 2020; 18 (12) 3222-3231
• 152 Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM, van Hout BA. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica 2011; 96 (05) 738-743
• 153 Croteau SE, Cook K, Sheikh L. et al. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm 2021; 27 (03) 316-326
• 154 Arshad S, Singh A, Awasthi NP, Kumari S, Husain N. Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy. Ther Adv Hematol 2018; 9 (08) 213-226
• 155 Marijke van den Berg H. Preventing bleeds by treatment: new era for haemophilia changing the paradigm. Haemophilia 2016; 22 (Suppl 5): 9-13
• 156 Lotfi F, Talebianpour H, Keshavarz K, Emadi F, Bordbar MR, Bastani P. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A. Daru 2020; 28 (01) 287-293
• 157 Kim HK, Peral C, Rubio-Rodríguez D, Rubio-Terrés C. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain. Expert Rev Pharmacoecon Outcomes Res 2021; 21 (02) 315-320
• 158 Gomes N. US FDA approves BioMarin's gene therapy for hemophilia A. Reuters; 2023
• 159 Franchini M, Mannucci PM. The safety of pharmacologic options for the treatment of persons with hemophilia. Expert Opin Drug Saf 2016; 15 (10) 1391-1400
• 160 Neumeyer J, Lin R-Z, Wang K. et al. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Adv 2019; 3 (24) 4166-4176
• 161 Cafuir LA, Kempton CL. Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol 2017; 8 (10) 303-313
• 162 Prezotti ANL, Frade-Guanaes JO, Yamaguti-Hayakawa GG, Ozelo MC. Immunogenicity of current and new therapies for hemophilia A. Pharmaceuticals (Basel) 2022; 15 (08) 911
• 163 Peyvandi F, Garagiola I, Abbattista M. Fitusiran in haemophilia: a breakthrough drug with many unknowns. Lancet 2023; 401 (10386): 1400-1401
• 164 Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci 2021; 28 (01) 64
• 165 Páramo JA. Treatment of haemophilia: from replacement to gene therapy. Med Clin 2021; 157 (12) 583-587
• 166 Reyes A, Révil C, Niggli M. et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin 2019; 35 (12) 2079-2087
• 167 Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol Ther 2022; 22 (09) 1099-1115
• 168 McIntosh J, Lenting PJ, Rosales C. et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013; 121 (17) 3335-3344
• 169 Pipe SW. Go long! A touchdown for factor VIII?. Blood 2010; 116 (02) 153-154
• 170 Pechtner V, Karanikas C, García-Pérez L, Glaesner W. A new approach to drug therapy: Fc-fusion technology. Prim Health Care 2017;7(01):